New antibody-chemo combo shows promise for mesothelioma

NCT ID NCT05918107

Completed Disease control Sponsor: Biotheus Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called PM8002, which targets two proteins that help cancer grow, combined with standard chemotherapy. It involved 31 adults with a rare cancer called malignant mesothelioma that could not be removed by surgery. The goal was to see if the combination shrinks tumors and is safe, but it is not a cure—patients may need ongoing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant mesothelioma malignant pleural mesothelioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MPM

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, China
Chinese PLA General Hospital

Beijing, China
Chongqing University Cancer Hospital

Chongqing, China
Fujian Cancer Hospital

Fuzhou, China
Harbin Medical University Cancer Hospital

Harbin, China
Henan Cancer Hospital

Zhengzhou, China
Jiangsu Province Hospital

Nanjing, China
Jilin Provincial Tumor Hospital

Changchun, China
Liaoning Cancer Hospital and Institute

Dalian, China
Peking Cancer Hospital

Beijing, China
Shandong Cancer Hospital

Jinan, China
Shanghai Pulmonary Hospital

Shanghai, China
The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, China
The First Hospital of Hebei Medical University

Shijiazhuang, China
Zhejiang Cancer Hospital

Hangzhou, China
Zhejiang Provincial People's Hospital

Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.